AR015241A1 - Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. - Google Patents
Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento.Info
- Publication number
- AR015241A1 AR015241A1 ARP990101019A ARP990101019A AR015241A1 AR 015241 A1 AR015241 A1 AR 015241A1 AR P990101019 A ARP990101019 A AR P990101019A AR P990101019 A ARP990101019 A AR P990101019A AR 015241 A1 AR015241 A1 AR 015241A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- cycloalkyl
- co2rg
- crg2
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 abstract 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 abstract 4
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 102100022337 Integrin alpha-V Human genes 0.000 abstract 1
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 methylenedioxy Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Antagonistas del receptor de vitronectina de formula (I) que son utiles en el tratamiento de osteosporosis: (I) en la que R* es II, X es CRR, NR o S;Y es CRR, NR o S; A es H, halo, ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, -S(O)rCF3, -CO2Rg, -CORg, -CONRg2, -alquilo C1-6, -alquil C0-6-Ar, -alquil C0-6-Het,-alquil C0-6-cicloalquilo C3-6, -S(O)kRg,o CH2N(Rf)2;R1 es-alquil C0-6-Het,-alquil C0-6-Ar, -alquilo C1-6, -H, -CN, -CH=CH2, -C=CH o -S(0)kRg; R2 es III, W es-(CHRg)a-U-(CHRg)b-; U está ausente o esCO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CR9(ORk)CRg2, CRgCRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O,C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2, N=N, NRgNRg, NRgNRg2, CRg2CRg, CRg2O, OCRg2, C=C, CRg=CRg, Ar o Het; G es NRe, su o; Rg es H, alquiloC1-6, cilcoalquil C3-7-alquilo C0-6 o Ar-alquilo C0-6; Rk es Rg, -C(O)Rg, o -C(O)ORf; Ri es H, alquilo C1-6, Het-alquilo C0-6, cicloalquil C3-7-alquilo C0-6,Ar-alquil C0-6 o alquilo C1-6 sustituido con uno a tres grupos seleccionados entre halogeno, CN, NRg2, ORg, SRg, CO2Rg y CON(Rg)2; Rf es H, alquilo C1-6 oAr-alquilo C0-6; Re es H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, cicloalquilo C3-7-alquilo C0-6 o (CH2)kCO2Rg; Rb y Rc se seleccionanindependientemente entreH, alquilo C1-6, Ar-alquil C0-6, Het-alquilo C0-6, cicloalquil C3-6-alquilo C0-6, halogeno, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2,CO(NRf)2,CH2N(Rf)2,o Rb y Rc están unidos entre sí para formar un anillo carbocíclico o heterocíclico,aromático o no aromático,de 5 o 6 miembros,opcionalmentesustituido hasta con 3 sustituyentes elegidos entre halogeno, CF3, alquilo C1-4, ORf, S(O)kRf, CORf, OH, NO2, N/Rf)2, CON(Rf)2 y CH2N(Rf); o metilendioxi; Q1,Q2, Q3 y Q4 son independientemente N o C-Ry, siempre que no más de uno de Q1,Q2,Q3 y Q4 sea N; R es H, alquilo C1-6, Ar-alquilo C0-6 o cicloalquil C3-6-alquilo C0-6; R es R, -C(O)R o -C(O)OR; Ry es H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3,-CF3S(O)r-, -CO2Rg o -CONRg2, o alquilo C1-6 opcionalmentesustituido con halo ORg, SRg,-CN,-NRgR, -NO2,-CF3,RS(O)r-, -CO2Rg, -CORg, o -CONRg2; a es 0, 1 o 2; b es 0, 1 o 2; k es 0, 1 o 2; r es 0, 1 o 2; s es 0, 1 o
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015241A1 true AR015241A1 (es) | 2001-04-18 |
Family
ID=26759473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101019A AR015241A1 (es) | 1998-03-10 | 1999-03-10 | Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (es) |
| JP (1) | JP2002506033A (es) |
| KR (1) | KR20010041812A (es) |
| CN (1) | CN1299282A (es) |
| AP (1) | AP2000001898A0 (es) |
| AR (1) | AR015241A1 (es) |
| AU (1) | AU758498B2 (es) |
| BG (1) | BG104824A (es) |
| BR (1) | BR9908636A (es) |
| CA (1) | CA2323208A1 (es) |
| CO (1) | CO5080762A1 (es) |
| DZ (1) | DZ2741A1 (es) |
| EA (1) | EA200000921A1 (es) |
| HU (1) | HUP0101143A3 (es) |
| ID (1) | ID26223A (es) |
| IL (1) | IL138245A0 (es) |
| NO (1) | NO20004503L (es) |
| OA (1) | OA12189A (es) |
| PE (1) | PE20000323A1 (es) |
| PL (1) | PL342881A1 (es) |
| SK (1) | SK13292000A3 (es) |
| TR (1) | TR200002625T2 (es) |
| UY (2) | UY25421A1 (es) |
| WO (1) | WO1999045927A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| PE20020665A1 (es) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| US20070275956A1 (en) * | 2003-10-14 | 2007-11-29 | Lohray Braj B | Novel Heterocyclic Compounds |
| RU2367661C2 (ru) * | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные тиазола |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP1879864A1 (en) | 2005-04-20 | 2008-01-23 | Janssen Pharmaceutica N.V. | Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls |
| DK3040329T3 (en) * | 2013-08-29 | 2019-01-28 | Kyoto Pharma Ind | AROMATIC RELATIONSHIP AND APPLICATION THEREOF IN THE TREATMENT OF DISEASES CONNECTED WITH BONE METABOLISM. |
| SI3050878T1 (sl) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te |
| JP6649902B2 (ja) | 2014-05-30 | 2020-02-19 | ファイザー・インク | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502704A (ja) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
| JP2000502708A (ja) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
-
1999
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/xx active
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Ceased
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Withdrawn
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200002625T2 (tr) | 2000-12-21 |
| UY25519A1 (es) | 1999-12-13 |
| ID26223A (id) | 2000-12-07 |
| OA12189A (en) | 2006-05-09 |
| PE20000323A1 (es) | 2000-05-24 |
| CN1299282A (zh) | 2001-06-13 |
| AU2903399A (en) | 1999-09-27 |
| BR9908636A (pt) | 2002-01-08 |
| AU758498B2 (en) | 2003-03-20 |
| HUP0101143A3 (en) | 2002-12-28 |
| CO5080762A1 (es) | 2001-09-25 |
| WO1999045927A1 (en) | 1999-09-16 |
| UY25421A1 (es) | 2001-07-31 |
| HUP0101143A2 (hu) | 2001-08-28 |
| AP2000001898A0 (en) | 2000-09-30 |
| CA2323208A1 (en) | 1999-09-16 |
| SK13292000A3 (sk) | 2001-06-11 |
| NO20004503D0 (no) | 2000-09-08 |
| BG104824A (en) | 2001-05-31 |
| EA200000921A1 (ru) | 2001-04-23 |
| KR20010041812A (ko) | 2001-05-25 |
| DZ2741A1 (fr) | 2003-09-08 |
| JP2002506033A (ja) | 2002-02-26 |
| PL342881A1 (en) | 2001-07-16 |
| IL138245A0 (en) | 2001-10-31 |
| EP1061921A1 (en) | 2000-12-27 |
| NO20004503L (no) | 2000-10-10 |
| EP1061921A4 (en) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015241A1 (es) | Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| AR011229A1 (es) | Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina. | |
| ES2617619T3 (es) | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| PE10499A1 (es) | Antagonistas del receptor de vitronectina | |
| AR050913A1 (es) | Compuestos derivados de tiazolpiridina como activadores de glucoquinasa; composiciones farmaceuticas que los contienen y su uso en medicamentos para el tratamiento de la diabetes tipo ii | |
| DE60318030D1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
| DK1404317T3 (da) | 5-Halogentryptaminderivater til anvendelse som ligander af 5-HT6- og/eller 5-HT7-serotoninreceptorer | |
| PE20010009A1 (es) | Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1 | |
| HRP20000896B1 (en) | Adenosine derivatives | |
| AR033791A1 (es) | Compuestos de acidos oxamicos y derivados como ligandos de receptores tiroideos,su uso. composicion y estuche que lo contiene | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| AR016433A1 (es) | Procedimiento para el tratamiento de la impotencia y composiciones. | |
| MX9700340A (es) | Agentes anti-helicobacter derivados sulfonamida de azolonas. | |
| ES2094843T3 (es) | Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos. | |
| RU2007138937A (ru) | Производные 1-бензилиндол-2-карбоксамида | |
| PE20081192A1 (es) | Tratamiento del dolor | |
| PA8463001A1 (es) | Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p | |
| AR021354A1 (es) | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica | |
| ES2054304T3 (es) | Feniletanolaminometiltetralinas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| ES2095277T3 (es) | 6,7-dihidro-3-fenil-1,2-benzoisoxazol-4(5h)-onas y -oles, un procedimiento para su preparacion y su uso como medicamentos. | |
| ES2089255T3 (es) | N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |